

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lim Application No. 10/618,540

Filed: July 9, 2003 Confirmation No.

For: HEMANGIOBLAST PROGENITOR

CELLS

Examiner:

Art Unit: Not yet assigned

Attorney Reference No. 4810-66314

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP MISSING PARTS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney for Applicant(s) William D Woons

Date Mailed November 10, 2003

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

MAIL STOP MISSING PARTS COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Applicant filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS.

However, if the Patent Office determines that a fee is required for Applicant to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Rτ

William D. Noonan M.D. Registration No. 30,878

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

Form	PTO-	1449	(Modifie	d)

Form PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS

FOR APPLICANT'S INFORMATION

STATEMENT

2011 E \	
Atty. Docket No. 4810-66314	Serial No. 10/618,540
NOV 1 2 2003 Applicant LIM, SAI K.	
Filing Date July 9, 2003	Group

REFERENCE DESIGNATION	II S DATENT DOCUMENTS
	TIAN FALIDITE INCULTIVE CONTRACT

EXAM. INIT.			D	OCUM	1ENT	NUM	BER		DATE	NAME	CLASS	SUB CLASS	FIL.DATE IF APPROPRIATE
	Al	5	3	9	9	3	4	6	21/03/1995	ANDERSON ET AL.	424	93.21	30/03/1997
	A2	5	5	9	9	7	0	3	04/02/1997	DAVIS ET AL.	435	373	28/10/1993
	A3	5	9	8	0	8	8	7	09/11/1999	ISNER ET AL	424	93.7	08/11/1996
	A4	6	4	1	0	0	1	5	25/06/2002	GORDON ET AL.	424	93.21	11/05/2000
	A5	0	0	6	8	0	4	5	06/05/2002	REUBINOFF ET AL.	424	93.7	14/03/2001

FOREIGN PATENT DOCUMENTS

ſ			DC	CLINA		HINAD	r.n		DATE	COLINEDA	CI AGG	SUB	TRANSI	LATION
l			DC	CUM	ENIN	NUMB	EK		DATE	COUNTRY	CLASS	CLASS	YES	NO
	A6	9	5	0	5	4	5	2	23/02/1995	wo				

OTHER ART (including Author, Title, Date, Pertinent Pages, Etc.)

	OTHER ART (including Author, Title, Date, Pertinent Pages, Etc.)
A7	BAHARY, N., and Zon, L.I. (2001). Development. Endotheliumchicken soup for the
	endoderm. Science 294, 530-531.
A8	BUSTELO, X.R., et al. (1993). Developmental expression of the vav protooncogene.
	Cell Growth Differ 4, 297-308.
A9	CARMELIET, P., et al. (1996). Abnormal blood vessel development and lethality in
	embryos lacking a single VEGF allele. Nature 380, 435-439.
A10	CHOI, K., et al. (1998). A common precursor for hematopoietic and endothelial cells.
	Development 125, 725-732.
A11	DAVIS, S., et al. (1996). Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by
	secretion-trap expression cloning. Cell 87, 1161-1169.
• A12	DOETSCHMAN, T.C., et al. (1985). The in vitro development of blastocyst-derived
	embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium.
	J Embryol Exp Morphol. 1985; 87:27-45.
A13	DZIERZAK, E. (1999). Embryonic beginnings of definitive hematopoietic stem cells.
	Ann N Y Acad Sci 872, 256-262; discussion 262-254.
A14	FERRARA, N., et al. (1996). Heterozygous embryonic lethality induced by targeted
	inactivation of the VEGF gene. Nature 380, 439-442.
A15	FISCHER, K.D., et al. (1995). Defective T-cell receptor signalling and positive selection
	of Vav-deficient CD4+ CD8+ thymocytes. Nature 374, 474-477.
A16	GODIN, I., et al. (1995). Emergence of multipotent hemopoietic cells in the yolk sac and
	paraaortic splanchnopleura in mouse embryos, beginning at 8.5 days postcoitus. Proc
	Natl Acad Sci U S A 92, 773-777.
A17	HAMAGUCHI, I., et al. (1999). In vitro hematopoietic and endothelial cell development
	from cells expressing TEK receptor in murine aorta-gonad-mesonephros region. Blood
	<i>93</i> , 1549-1556.
A18	HERRMANN, B.G., and Kispert, A. (1994). The T genes in embryogenesis. Trends
	Genet 10, 280-286.
A19	HROMAS, R., et al. (1993). Hematopoietic lineage- and stage-restricted expression of
	the ETS oncogene family member PU.1. Blood 82, 2998-3004.
A20	JIANG, Y., et al. (2002). Pluripotency of mesenchymal stem cells derived from adult
	marrow. Nature 418, 41-49.
A21	KATZAV, S., et al. (1989). vav, a novel human oncogene derived from a locus
	ubiquitously expressed in hematopoietic cells. Embo J 8, 2283-2290.
A22	KELLER, G. (2001). The Hemangioblast. In Stem Cell Biology, D.R. Marshak,
	R.L. Gardener, and D. Gottlieb, eds. (Cold Spring Harbor, Cold Spring Harbor
	Laboratory Press), pp. 329-348.
A23	KELLER, G., et al. (1993). Hematopoietic commitment during embryonic stem cell
	differentiation in culture. Mol Cell Biol 13, 473-486.

•	A24 1	Maria Para Para Para Para Para Para Para
	A24	KELLER, G., et al. (1999). Development of the hematopoietic system in the mouse. Exp Hematol 27, 777-787.
	B "	N 1 2 2013KHNNEDY, M., et al. (1997). A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature 386, 488-493.
	A26	LAMMERT, E., et al. (2001). Induction of pancreatic differentiation by signals from blood vessels. Science 294, 564-567.
	A27	LEVENBERG S., et al. (2002) Endothelial cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A. 99, 4391-4396.
	A28	LIM, S.K., et al. (1998). Increased susceptibility in Hp knockout mice during acute hemolysis. Blood 92, 1870-1877.
	A29	LIN, C.S., et al. (1996). Differential effects of an erythropoietin receptor gene disruption
	A30	on primitive and definitive erythropoiesis. Genes Dev 10, 154-164. MATSUMOTO, K., et al. (2001). Liver organogenesis promoted by endothelial cells
	A31	prior to vascular function. Science 294, 559-563. MCKERCHER, S.R., et al. (1996). Targeted disruption of the PU.1 gene results in
	A32	multiple hematopoietic abnormalities. Embo J 15, 5647-5658. MERCER, E.H., et al. (1991). The dopamine beta-hydroxylase gene promoter directs
		expression of E. coli lacZ to sympathetic and other neurons in adult transgenic mice. Neuron 7, 703-716.
	A33	MOMBAERTS, P., et al. (1992). RAG-1 deficient mice have no mature B and T lymphocytes. Cell 68, 869-877.
	A34	MOORE, M.S.A., and Metcalf, D. (1970). Ontogeny of the hematopoietic system: Yolk sac origin of <i>in vivo</i> and <i>in vitro</i> colony forming cells in the mouse embryo. Br J Hematology 18, 279-296.
	A35	MULLER, A.M., et al. (1994). Development of hematopoietic stem cell activity in the mouse embryo. Immunity 1, 291-301.
	A36	MURRAY, P.D.F. (1932). The development <i>in vitro</i> of the blood of the early chick embryo. Proc Roy Soc London 11, 497-521.
	A37	NERLOV, C., and Graf, T. (1998). PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev 12, 2403-2412.
	A38	NISHIKAWA, S.I., et al. (1998). Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages. Development 125, 1747-1757.
	A39	ORKIN, S.H. (2001). Hematopoietic Stem Cells: Molecular Diversification and Developmental Interrelationships. In Stem Cell Biology, D.R. Marshak, R.L. Gardener,
	A40	and D. Gottlieb, eds. (Cold Spring Harbor, Cold Spring Harbor Laboratory Press). PEVNY, L., et al. (1991). Erythroid differentiation in chimaeric mice blocked by a
	A31	targeted mutation in the gene for transcription factor GATA-1. Nature 349, 257-260. ROBB, L., et al. (1996). The scl gene product is required for the generation of all
	A42	hematopoietic lineages in the adult mouse. Embo J 15, 4123-4129. ROBERTSON, E.J. (1987). Embryo-derived stem cell lines. In Teratocarcinomas and
		embryonic stem cells: a practical approach., E.J. Robertson, ed. (Oxford, IRL Press Limited), pp. 71-112.
	A43	ROGERS, M.B., et al. (1991). Specific expression of a retinoic acid-regulated, zinc-finger gene, Rex-1, in preimplantation embryos, trophoblast and spermatocytes. Development 113, 815-824.
	A44	SABIN, E.R. (1920). Studies on the origin of blood vessels and of red corpuscles as seen in the living blastoderm of the chick during the second day of incubation. Contributions to Embryology 9, 213-262.
	A45	SCOTT, E.W., et al. (1994). Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265, 1573-1577.
	A46	SHALABY, F., et al. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66.
	A47	SIMON, M.C., et al. (1992). Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells. Nat Genet 1, 92-98.
	A48	SMITH, J. (1997). Brachyury and the T-box genes. Curr Opin Genet Dev 7, 474-480.
	A49	SURI, C., et al. (1998). Increased vascularization in mice overexpressing angiopoietin-1. Science 282, 468-471.
	A50	TAKAKURA, N., et al. (1998). Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity 9, 677-686.

.A51	TARAKHOVSKY, A., et al. (1995). Defective antigen receptor-mediated proliferation
	by B and T cells in the absence of Vav. Nature 374, 467-470.
A52 NOV 1	7 2003 TECHNAU, U. (2001). Brachyury, the blastopore and the evolution of the mesoderm. Bioessays 23, 78-794.
A53	WILES, M.V. (1993) Embryonic stem cell differentiation in vitro. Methods in
THE TOPAC	Enzymology. 225, 900-918.
A54	WU, H., et al. (1995). Generation of committed erythroid BFU-E and CFU-E
	progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83, 59-67
EXAMINER	DATE CONSIDERED

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JDM:RTG:jcb:aet